pharmaphorum April 2, 2024
Phil Taylor

Otsuka and Click Therapeutics’ Rejoyn has become the first prescription digital therapeutic (DTx) to be approved by the FDA for people with major depressive disorder.

Rejoyn (formerly CT-152), a software-as-a-medical device (SaMD) delivered via a smartphone app, has been authorised as an add-on to clinician-managed outpatient care for adults aged 22 and over with MDD who require antidepressant medicines.

Delivered over six weeks, the DTx is designed to help alleviate MDD symptoms using a combination of cognitive emotional training exercises and brief therapeutic lessons. It is due to be available for download from app stores for iOS and Android in the second half of this year.

Rejoyn is the first fruit of a collaboration set up in 2019 with Otsuka,...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

Continue Reading

 
Topics: Apps, Digital Health, FDA, Govt Agencies, Medical Devices, Technology
Related Articles:
FDA guidance eases wearables oversight. But experts have questions about what’s next.
AI Model FDA-Cleared to Triage 14 Conditions
The Promise And Perils Of FDA’s New ‘Plausible Mechanism’ Pathway (Part 2)
FDA Updates Two Digital Health Final Guidance Documents
FDA in Flux — January 2026 Newsletter

Share Article